Imperial College London

Dr Sara Bonvini

Faculty of MedicineNational Heart & Lung Institute

Academic Visitor
 
 
 
//

Contact

 

+44 (0)20 7594 8397sara.bonvini10

 
 
//

Location

 

102Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Maher:2015:10.1183/09031936.00061614,
author = {Maher, SA and Birrell, MA and Adcock, JJ and Wortley, MA and Dubuis, ED and Bonvini, SJ and Grace, MS and Belvisi, MG},
doi = {10.1183/09031936.00061614},
journal = {European Respiratory Journal},
pages = {1108--1118},
title = {Prostaglandin D-2 and the role of the DP1, DP2 and TP receptors in the control of airway reflex events},
url = {http://dx.doi.org/10.1183/09031936.00061614},
volume = {45},
year = {2015}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - Prostaglandin D2 (PGD2) causes cough and levels are increased in asthma suggesting that it may contribute to symptoms. Although the prostaglandin D2 receptor 2 (DP2) is a target for numerous drug discovery programmes little is known about the actions of PGD2 on sensory nerves and cough.We used human and guinea pig bioassays, in vivo electrophysiology and a guinea pig conscious cough model to assess the effect of prostaglandin D2 receptor (DP1), DP2 and thromboxane receptor antagonism on PGD2 responses.PGD2 caused cough in a conscious guinea pig model and an increase in calcium in airway jugular ganglia. Using pharmacology and receptor-deficient mice we showed that the DP1 receptor mediates sensory nerve activation in mouse, guinea pig and human vagal afferents. In vivo, PGD2 and a DP1 receptor agonist, but not a DP2 receptor agonist, activated single airway C-fibres. Interestingly, activation of DP2 inhibited sensory nerve firing to capsaicin in vitro and in vivo.The DP1 receptor could be a therapeutic target for symptoms associated with asthma. Where endogenous PGD2 levels are elevated, loss of DP2 receptor-mediated inhibition of sensory nerves may lead to an increase in vagally associated symptoms and the potential for such adverse effects should be investigated in clinical studies with DP2 antagonists.
AU - Maher,SA
AU - Birrell,MA
AU - Adcock,JJ
AU - Wortley,MA
AU - Dubuis,ED
AU - Bonvini,SJ
AU - Grace,MS
AU - Belvisi,MG
DO - 10.1183/09031936.00061614
EP - 1118
PY - 2015///
SN - 0903-1936
SP - 1108
TI - Prostaglandin D-2 and the role of the DP1, DP2 and TP receptors in the control of airway reflex events
T2 - European Respiratory Journal
UR - http://dx.doi.org/10.1183/09031936.00061614
UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000352023800023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR - https://erj.ersjournals.com/content/45/4/1108.
VL - 45
ER -